The Differences in Adverse Maternal and Fetal Outcomes Related to Hypertension in Obese Versus Non-obese Pregnant Women
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 260
- 试验地点
- 1
- 主要终点
- The rate of adverse maternal outcome related to hypertension in both groups
研究概览
简要总结
Hypertensive disorders of pregnancy, include pre-existing and gestational hypertension, preeclampsia, and eclampsia, it complicates up to 10% of pregnancies and represents a significant cause of maternal and perinatal morbidity and mortality. Following the "National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy" recommendation is currently a systolic blood pressure (SBP) ⩾ of 140 mmHg and diastolic blood pressure (DBP) ⩾ of 90 mmHg. The diagnosis generally requires two separate measurements. Accepted across international guidelines are the following four categories: Chronic/pre-existing hypertension (Hypertension discovered preconception or prior to 20 weeks gestation), Gestational hypertension (Hypertension that appears de novo after 20 weeks gestation and normalizes after pregnancy), Preeclampsia-eclampsia (De novo hypertension after 20 weeks' gestation accompanied by proteinuria, other features of maternal organ dysfunction or uteroplacental dysfunction), Chronic/pre-existing hypertension with superimposed preeclampsia-eclampsia. Over the past 2 decades, extensive epidemiologic studies have clearly established that obesity is a major risk for gestational hypertension and preeclampsia. The risk of preeclampsia typically doubles with each 5-7 kg/m2 increase in pre-pregnancy. The mechanisms have only been partially explored; increased cytokine-mediated inflammation and oxidative stress, increased shear stress, dyslipidemia, and increased sympathetic activity1 have all been proposed as possible pathways. Few studies have examined the relationship between pre-pregnancy BMI, gestational weight gain (GWG), and the risk of preeclampsia. So, our study aims to evaluate the adverse maternal and fetal outcomes related to hypertension in obese and non-obese pregnant women.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 25 Years 至 35 Years(Adult)
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Women aged from 20-35 years.
- •Pregnant women from 28-30 weeks.
- •Pregnant women with a singleton pregnancy.
- •Women with chronic or gestational hypertension.
- •Women with normal baseline investigations (uncomplicated hypertension).
- •Obese women and non-obese women.
排除标准
- •Women with preeclampsia/eclampsia.
- •Women need urgent termination of pregnancy.
- •Women with co-morbidities such as diabetes, renal diseases, cardiac ...etc.
- •Women with confirmed fetal malformation.
- •Women who will refuse to participate.
研究组 & 干预措施
Obese hypertensive pregnant women
干预措施: Anti-Hypertensive (Drug)
Non-obese hypertensive pregnant women
干预措施: Anti-Hypertensive (Drug)
Non-obese hypertensive pregnant women
干预措施: Ultrasound (Radiation)
Non-obese hypertensive pregnant women
干预措施: Doppler ultrasound (Radiation)
Non-obese hypertensive pregnant women
干预措施: complete blood count (Diagnostic Test)
Non-obese hypertensive pregnant women
干预措施: Body mass index (Diagnostic Test)
Obese hypertensive pregnant women
干预措施: Ultrasound (Radiation)
Obese hypertensive pregnant women
干预措施: Doppler ultrasound (Radiation)
Obese hypertensive pregnant women
干预措施: complete blood count (Diagnostic Test)
Obese hypertensive pregnant women
干预措施: Body mass index (Diagnostic Test)
结局指标
主要结局
The rate of adverse maternal outcome related to hypertension in both groups
时间窗: 3 month
次要结局
未报告次要终点
研究者
Mohammed Khairy Ali
Assistant Professor
Assiut University
